{
    "clinical_study": {
        "@rank": "78800", 
        "arm_group": {
            "arm_group_label": "Vorinostat & Bevacizumab", 
            "arm_group_type": "Experimental", 
            "description": "Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day."
        }, 
        "brief_summary": {
            "textblock": "It has been shown that bevacizumab has significant anti-tumor activity in patients with\n      recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against\n      malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics.\n      Patients will be treated with a combination of bevacizumab and vorinostat."
        }, 
        "brief_title": "Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Recurrent Glioblastoma Multiforme", 
            "Malignant Glioma", 
            "Adult Brain Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Glioblastoma", 
                "Glioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "There is no effective therapy for patients with recurrent glioblastoma multiforme (GBM)\n      hence such patients remain a major unmet need in oncology. The investigators have recently\n      demonstrated that bevacizumab (BV), a humanized monoclonal antibody against vascular\n      endothelial growth factor, has significant anti-tumor activity among recurrent glioblastoma\n      multiforme patients. Vorinostat has modest anti-tumor activity against malignant glioma and\n      can potentiate the action of both chemotherapy and anti-angiogenics. The current study is\n      designed to evaluate the anti-tumor activity of vorinostat when combined with BV among\n      recurrent glioblastoma multiforme patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years.\n\n          -  An interval of at least 4 weeks between prior surgical resection or one week from\n             stereotactic biopsy.\n\n          -  An interval of at least 12 weeks from the end of prior radiotherapy unless there is a\n             new area of enhancement consistent with recurrent tumor outside of the radiation\n             field, or there is biopsy-proven tumor progression\n\n          -  An interval of at least 4 weeks from prior chemotherapy [6 weeks for nitrosoureas, 1\n             week for daily administered chemotherapy (metronomic dosing)] or investigational\n             agent unless the patient has recovered from all anticipated toxicities associated\n             with that therapy.\n\n          -  Eastern Cooperative Oncology Group (ECOG) 0-1.\n\n          -  Hematocrit \u2265 29%, hemoglobin \u2265 9, absolute neutrophil \u22651,500 cells/microliter,\n             platelets \u2265 100,000 cells/microliters.\n\n          -  Serum creatinine, serum glutamic oxaloacetic transaminase(SGOT) and bilirubin < 1.5\n             times upper limit of normal.\n\n          -  Signed informed consent approved by the Institutional Review Board prior to patient\n             entry.\n\n          -  No evidence of hemorrhage on the baseline MRI or CT scan other than those that are\n             stable grade 1.\n\n          -  If sexually active, patients will take contraceptive measures for the duration of the\n             treatments. Medically acceptable contraceptives include: (1) surgical sterilization\n             (such as a tubal ligation, hysterectomy, vasectomy), (2) approved hormonal\n             contraceptives (such as birth control pills, patches, implants or injections), (3)\n             barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an\n             intrauterine device (IUD).\n\n        Exclusion Criteria:\n\n        Disease-specific exclusions\n\n          -  More than 2 prior episodes of disease progression\n\n          -  Prior therapy with histone deacetylase inhibitors; valproic acid is not permitted and\n             patients previously treated with valproic acid must be off valproic acid for at least\n             30 days prior to initiation of study medication\n\n          -  Prior bevacizumab therapy\n\n          -  Co-medication that may interfere with study results; e.g. immuno-suppressive agents\n             other than corticosteroids\n\n          -  Active infection requiring intravenous antibiotics\n\n          -  Severe hepatic insufficiency, active viral hepatitis or HIV infection\n\n          -  Requires therapeutic anti-coagulation with warfarin\n\n        General medical exclusions\n\n        Subjects meeting the following criteria are ineligible for study entry:\n\n          -  Inability to comply with study and/or follow-up procedures\n\n        Bevacizumab-specific exclusions\n\n          -  Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or\n             diastolic blood pressure > 100 mmHg on antihypertensive medications)\n\n          -  Any prior history of hypertensive crisis or hypertensive encephalopathy\n\n          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see\n             Appendix E)\n\n          -  History of myocardial infarction or unstable angina within 6 months prior to study\n             enrollment\n\n          -  History of stroke or transient ischemic attack within 6 months prior to study\n             enrollment\n\n          -  Significant  vascular disease (e.g., aortic aneurysm, aortic dissection)\n\n          -  Symptomatic peripheral vascular disease\n\n          -  Evidence of bleeding diathesis or coagulopathy\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             prior to study enrollment or anticipation of need for major surgical procedure during\n             the course of the study\n\n          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular\n             access device, within 7 days prior to study enrollment\n\n          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess within 6 months prior to study enrollment\n\n          -  Serious, non-healing wound, ulcer, or bone fracture\n\n          -  Proteinuria at screening as demonstrated by either:\n\n               -  Urine protein:creatinine (UPC) ratio  >= 1.0 at screening OR\n\n               -  Urine dipstick for proteinuria \u2265 2+ (patients discovered to have \u22652+ proteinuria\n                  on dipstick urinalysis at baseline should undergo a 24 hour urine collection and\n                  must demonstrate \u2264 1g of protein in 24 hours to be eligible).\n\n          -  Known hypersensitivity to any component of bevacizumab\n\n          -  Pregnant (positive pregnancy test) or lactating. Refuse the use of effective means of\n             contraception (men and women) in subjects of child-bearing potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738646", 
            "org_study_id": "Pro00024983"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vorinostat & Bevacizumab", 
                "intervention_name": "Vorinostat", 
                "intervention_type": "Drug", 
                "other_name": "SAHA"
            }, 
            {
                "arm_group_label": "Vorinostat & Bevacizumab", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vorinostat", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "vorinostat", 
            "SAHA", 
            "bevacizumab", 
            "AVASTIN", 
            "malignant glioma", 
            "GBM", 
            "glioblastoma multiforme", 
            "brain tumor"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "link": [
            {
                "description": "Link to the Preston Robert Tisch Brain Tumor Center", 
                "url": "http://www.cancer.duke.edu/btc/"
            }, 
            {
                "description": "Duke Cancer Institute", 
                "url": "http://www.dukecancerinstitute.org/"
            }, 
            {
                "description": "Duke Cancer Center - Patient Care", 
                "url": "http://www.dukehealth.org/cancer"
            }
        ], 
        "location": {
            "contact": {
                "email": "shelley.keats@dm.duke.edu", 
                "last_name": "Shelley Dutton, BS", 
                "phone": "919-668-0673"
            }, 
            "contact_backup": {
                "email": "katherine.peters@dm.duke.edu", 
                "last_name": "Katherine Peters, MD, PhD", 
                "phone": "919-684-3914"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Katherine Peters, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Annick Desjardins, MD, FRCPC", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Henry S Friedman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tulika Ranjan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gordana Vlahovic, MD, MHS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lloyd Alderson, MD, D.Sc.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients", 
        "overall_contact": {
            "email": "katherine.peters@dm.duke.edu", 
            "last_name": "Katherine Peters, MD, PhD", 
            "phone": "919-684-3914"
        }, 
        "overall_contact_backup": {
            "email": "shelley.keats@dm.duke.edu", 
            "last_name": "Shelley Dutton, BS", 
            "phone": "919-668-0673"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Katherine Peters, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "6-month progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738646"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "MRI evaluations for assessment of radiographic response and response will be classified according to the Response Assessment in Neuro-Oncology criteria. Brain MRI will be performed prior to the initiation of every other cycle. Comparisons of objective assessments, excluding progressive disease, are based upon major changes in tumor size on the Gd-MRI scan compared to the baseline scan.  Determination of progressive disease is based upon comparison to the previous scan with the smallest measurements.", 
                "measure": "Radiographic Response", 
                "safety_issue": "No", 
                "time_frame": "2.5 Years"
            }, 
            {
                "description": "Grade 3 or greater, treatment related, non-hematologic toxicities.", 
                "measure": "Safety & Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "2.5 Years"
            }, 
            {
                "measure": "Median progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "2.5 Years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2.5 Years"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Genentech", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}